Transcranial Magnetic Stimulation to Slow Down Cognitive Decline in Alzheimer's Disease

New amyloid-targeting drugs for Alzheimer's disease (AD) offer minimal or unclear efficacy and often cause adverse events, highlighting the need for new therapies. In recent years, repetitive transcranial magnetic stimulation (rTMS) has shown increasing success. A recent randomized, double-blind, sham-controlled, phase 2 demonstrated promising results from a 24-week rTMS treatment protocol targeting the precuneus. This brain region is considered a main hub of the human brain connectome and a prominent area of AD pathology. The results showed stable cognitive performance and increased brain activity in the treatment group, whereas the sham group worsened. A replication study is planned to further investigate the working mechanism of precuneus-rTMS in AD and to improve understanding of its therapeutic potential.

NCT Number	NCT07036328
Lead Sponsor	Willem de Haan
Conditions	Alzheimer Disease, Alzheimer Disease, Early Onset
Enrollment	55 participants
Start Date	2025-04-07
Primary Completion	2028-01 (estimated)
Study Completion	2028-07 (estimated)
Updated on ClinicalTrials.gov	2026-05-12